Compare GSK plc (GSK) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Schlumberger NV — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Schlumberger NV for 99 Days on average.
| GSK | SLB | |
|---|---|---|
Market Cap | $91.88B | $72.69B |
Volume | 7,730,529 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $61.18 | $60.10 |
52-Week Low | $43.24 | $31.72 |
Typical Hold Time | 93 Days | 99 Days |
Enterprise Value | $111.88B | $81.42B |
Dividend Yield | 3.9% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SLB trades at $48.98, up 2.13% today, with strong analyst support (85% buy ratings) and a $64.58 consensus price target suggesting 32% upside. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand revenue visibility, though technical indicators show bearish momentum. The company maintains solid profitability with 8.53% net margins and consistent earnings beats in recent quarters.
SLB's multi-year contracts provide stable revenue streams, but declining profit margins and bearish technicals present near-term headwinds. The stock offers value with reasonable valuation multiples (P/E 23.89) and dividend income, though energy sector volatility and execution risks on new projects require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
